Clinical Trials Logo

Advanced Lymphoma clinical trials

View clinical trials related to Advanced Lymphoma.

Filter by:

NCT ID: NCT04999384 Recruiting - Clinical trials for Advanced Solid Tumor

First in Human, Dose Escalation Study of AN4005

Start date: September 27, 2021
Phase: Phase 1
Study type: Interventional

Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional "3 + 3 design" will be utilized for dose finding with dose escalation and/or de-escalation as appropriate.

NCT ID: NCT04609579 Terminated - Clinical trials for Advanced Solid Tumor

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Start date: November 18, 2020
Phase: Phase 1
Study type: Interventional

This clinical trial is evaluating a drug called SNX281 given by itself and in combination with pembrolizumab (KEYTRUDA®) in participants with advanced solid tumors and lymphoma. The main goals of this study are to: - Find the recommended dose of SNX281 that can be given to participants safely alone and in combination with pembrolizumab (KEYTRUDA®). - Learn more about the side effects and safety profile of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®) - Learn more about pharmacological characteristics of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®) - Learn more about effectiveness of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®)

NCT ID: NCT04470947 Recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

EXALT-2
Start date: June 10, 2020
Phase:
Study type: Observational [Patient Registry]

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

NCT ID: NCT04439357 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Start date: February 25, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has genetic changes called GNAQ or GNA11 mutations. Trametinib may block proteins called MEK1 and MEK2, which may be needed for cancer cell growth when GNAQ or GNA11 mutations are present. Researchers hope to learn if trametinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439344 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Start date: May 31, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation. Binimetinib blocks proteins called MEK1 and MEK2, which may be needed for cancer cell growth when an NRAS mutation is present. Researchers hope to learn if binimetinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439331 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of VS-6063 (defactinib) in patients whose cancer has a genetic change called NF2 mutation. Defactinib may block a protein called FAK, which may be needed for cancer cell growth when NF2 mutations are present. Researchers hope to learn if defactinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439318 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Start date: February 25, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has a has a genetic change called NF1 mutation. Trametinib blocks proteins called MEK1 and MEK2, which may be needed for cancer cell growth when an NF1 mutation is present. Researchers hope to learn if trametinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439305 Withdrawn - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Start date: February 25, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of dasatinib in patients whose cancer has a genetic change called DDR2 mutation. Dasatinib may block proteins called tyrosine kinases, which may be needed for cancer cell growth. Researchers hope to learn if dasatinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439292 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of trametinib and dabrafenib in patients whose cancer has genetic changes called BRAF V600 mutations. Dabrafenib may stop the growth of cancer by blocking BRAF proteins which may be needed for cell growth. Trametinib may stop the growth of cancer cells by blocking MEK proteins which, in addition to BRAF proteins, may also be needed for cell growth. Researchers hope to learn if giving trametinib with dabrafenib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439279 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of trametinib in patients with cancer having genetic changes called BRAF mutations and fusions. Trametinib may block proteins called MEK1 and MEK2, which may be needed for growth of cancer cells that express BRAF mutations. Researchers hope to learn if giving trametinib will shrink this type of cancer or stop its growth.